Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Caladrius Bio (CLBS)

Caladrius Bio (CLBS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 63,295
  • Shares Outstanding, K 32,966
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,360 K
  • 60-Month Beta 1.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.98
Trade CLBS with:

Options Overview

Details
  • Implied Volatility 173.44%
  • Historical Volatility 132.53%
  • IV Percentile 33%
  • IV Rank 13.16%
  • IV High 898.77% on 11/16/20
  • IV Low 63.52% on 07/09/20
  • Put/Call Vol Ratio 0.06
  • Today's Volume 5,334
  • Volume Avg (30-Day) 5,189
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 42,603
  • Open Int (30-Day) 27,325

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.12
  • Number of Estimates 1
  • High Estimate -0.12
  • Low Estimate -0.12
  • Prior Year -0.38
  • Growth Rate Est. (year over year) +68.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5600 +23.08%
on 02/23/21
3.0500 -37.05%
on 02/11/21
-0.1600 (-7.69%)
since 02/01/21
3-Month
1.2500 +53.60%
on 12/14/20
4.8900 -60.74%
on 01/20/21
+0.4200 (+28.00%)
since 12/01/20
52-Week
1.0500 +82.86%
on 03/19/20
4.8900 -60.74%
on 01/20/21
-0.6500 (-25.29%)
since 02/28/20

Most Recent Stories

More News
Caladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Company demonstrates resilience despite COVID-19 challenges: Financial situation secure and development programs progressing

CLBS : 1.9200 (+7.87%)
Caladrius Biosciences, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 25, 2021 / Caladrius Biosciences, Inc. (NASDAQ:CLBS) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 25,...

CLBS : 1.9200 (+7.87%)
Caladrius Biosciences to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today...

CLBS : 1.9200 (+7.87%)
Longeveron Inc. Announces the Appointment of Prominent Biotech, Capital Markets and Corporate Finance Executives to the Board of Directors

Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced...

LGVN : 7.90 (-1.25%)
CLBS : 1.9200 (+7.87%)
Caladrius Biosciences, Inc. Closes $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today...

CLBS : 1.9200 (+7.87%)
Caladrius Biosciences, Inc. Announces $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today...

CLBS : 1.9200 (+7.87%)
New Strong Sell Stocks for February 4th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

GD : 167.06 (+2.20%)
AVB : 177.02 (+0.72%)
HAYN : 29.79 (+6.66%)
CLBS : 1.9200 (+7.87%)
BILI : 144.67 (+14.84%)
New Strong Sell Stocks for January 29th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

TNP : 9.08 (-1.84%)
ASC : 3.80 (-3.55%)
EURN : 9.05 (+2.49%)
CLBS : 1.9200 (+7.87%)
USAS : 2.50 (-4.21%)
Caladrius Biosciences Closes $25.0 Million Private Placement

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today...

CLBS : 1.9200 (+7.87%)
Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in February 2021

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today...

CLBS : 1.9200 (+7.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve...

See More

Key Turning Points

3rd Resistance Point 2.1167
2nd Resistance Point 2.0333
1st Resistance Point 1.9767
Last Price 1.9200
1st Support Level 1.8367
2nd Support Level 1.7533
3rd Support Level 1.6967

See More

52-Week High 4.8900
Fibonacci 61.8% 3.4231
Fibonacci 50% 2.9700
Fibonacci 38.2% 2.5169
Last Price 1.9200
52-Week Low 1.0500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar